Poxel SA

7PO

Company Profile

  • Business description

    Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

  • Contact

    259/261 Avenue Jean Jaures
    Immeuble le Sunway
    Lyon69007
    FRA

    T: +33 437372010

    https://www.poxel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    5

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,545.29208.55-0.88%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,954.87707.15-1.19%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,577.0325.54-0.71%

Market Movers